ROS-Responsive Nano-Encapsulated Selenium Targeting Cervical Cancer Cell via PI3K/AKT Signaling Pathway.
Current cervical cancer treatments have yet to realize significant advances in patient quality of life. To overcome the challenges of off-target toxicity and inefficient delivery, we developed targeted ROS-responsive selenium nanoparticles, based on selenium's anticancer properties.
FA-ReRSeNPs were synthesized and subjected to systematic characterization of their physicochemical and biological properties. The anti-tumor activity of FA-ReRSeNPs, along with the mechanistic basis, was validated using integrated in vitro assays and in vivo animal models.
Using human cervical cancer cells (Hela and SiHa) and a SiHa subcutaneous xenograft nude mouse model, we verified that FA-ReRSeNPs significantly reduced the selenium dose required for anticancer activity, while alleviating off-target damage to normal tissues. Mechanistic studies confirmed that FA-ReRSeNPs exert anticancer effects via inhibition of PI3K/AKT signaling pathway; this inhibition subsequently induces tumor cell apoptosis and restrains proliferation. Cross-validated results from in vitro assays and in vivo burden analyses demonstrate that FA-ReRSeNPs possess superior tumor-inhibitory potential with high targeting specificity.
This work confirms FA-ReRSeNPs as a precision-driven nanotherapeutic for cervical cancer management. The fusion of active targeting and ROS-responsive release mechanisms addresses the classic efficacy-toxicity dilemma of conventional anticancer agents, highlighting the translational value of intelligent nanoengineering in advancing cancer therapies.
FA-ReRSeNPs were synthesized and subjected to systematic characterization of their physicochemical and biological properties. The anti-tumor activity of FA-ReRSeNPs, along with the mechanistic basis, was validated using integrated in vitro assays and in vivo animal models.
Using human cervical cancer cells (Hela and SiHa) and a SiHa subcutaneous xenograft nude mouse model, we verified that FA-ReRSeNPs significantly reduced the selenium dose required for anticancer activity, while alleviating off-target damage to normal tissues. Mechanistic studies confirmed that FA-ReRSeNPs exert anticancer effects via inhibition of PI3K/AKT signaling pathway; this inhibition subsequently induces tumor cell apoptosis and restrains proliferation. Cross-validated results from in vitro assays and in vivo burden analyses demonstrate that FA-ReRSeNPs possess superior tumor-inhibitory potential with high targeting specificity.
This work confirms FA-ReRSeNPs as a precision-driven nanotherapeutic for cervical cancer management. The fusion of active targeting and ROS-responsive release mechanisms addresses the classic efficacy-toxicity dilemma of conventional anticancer agents, highlighting the translational value of intelligent nanoengineering in advancing cancer therapies.
Authors
Qiu Qiu, Hu Hu, Zhao Zhao, Chen Chen, Shen Shen, Dai Dai, Ban Ban, Ma Ma, Weng Weng, Huang Huang, Zhu Zhu, Zhao Zhao, Guo Guo
View on Pubmed